</s><s><s><s> human papillomaviruses 6, 11, 16, and 18 are the most common causes of cervical cancer in the united states. 
 prophylactic vaccines against these viruses have been shown to be safe and effective in reducing the incidence of cervical infection and precancer caused by non-vaccine oncogenic nonvaccine types. in this review, 
 recommendations and reports are provided for clinical trials of human papllomavirus prophy and cancer vaccines, including those for the prevention of high-grade cervical lesions. </s>